Q&A with Robert Brooke, CEO of Vitality Biopharma

Google+ Pinterest LinkedIn Tumblr +

 

Financial Press: Robert, could you give us a little bit of a rundown of your company? An elevator pitch, so to speak.

RB: Sure, Vitality Biopharma is an early-stage, drug-development company that’s developed a novel class of cannabinoid pharmaceuticals. Our class of cannabinoid pharmaceuticals are prodrugs that release cannabinoids in a targeted fashion within the GI tract, and they do this in a way that eliminates all drug psycho-activity or intoxication.

FP:  Are you talking about CBD? The derivative of cannabis that seems to be taking the nutraceutical markets by storm?

RB: Our compounds are prodrugs of not only CBD, which is not intoxicating, but also THC, which is the principal compound that is psychoactive within cannabis. But we have developed a novel, prodrug technology that enables targeting of THC, CBD, and other cannabinoids to the colon, where it can be restricted to that region, provide local relief of pain and inflammation and avoid systemic delivery. So, it avoids the intoxication that occurs when THC is delivered into the bloodstream and brain.

FP: That’s very impressive. So, how does your company go about actually targeting the gut and targeting those areas of the body without going throughout the blood system?

RB: Vitality is one of the few groups in the world that has pioneered a process of enzymatic glycosylation. So, we can take any cannabinoid and effectively tack on a glucose moiety or sugar moiety to that compound. And what that enables us to do is create this new class of compounds that are very water soluble and stable and that they can be formulated as oral pharmaceuticals. So you can deliver them just through a simple pill or capsule.

And the glycosylation process enables us to take a cannabinoid after it’s been formulated within a capsule and it transits all the way through the GI tract to the colon or large intestine and that’s where your gut microbes secrete enzymes that cleave off the sugar.

They want to grab that sugar as energy or fuel, and then they release the cannabinoids. That’s where compounds like THC can coat and cool the intestines, providing relief of pain and inflammation and do it without entry into the bloodstream or brain.

FP: Well that sounds fantastic. So, tell me a little bit more about the background and history of Vitality.

I understand your company used to mainly deal with glucose or stevia as a primary target before. Has that sort of led us to the story as to where we are today?

RB: Exactly. So Vitality Biopharma (is a) company that originally was developing a bioprocessing technique to make stevia taste better. And stevia is a high-potency, zero calorie sweetener that’s derived from the stevia plant and the way that product is made within the plant is through this enzymatic glycosylation process.

And a discovery that we made in late 2015 was that this enzyme derived from the stevia plant ended up being a lot more promiscuous and a lot more useful than anyone had ever realized. And so, it not only could modify or glycosylate stevia products, but it could modify cannabinoids, and many other compounds.

It was around late 2015, when we’re one of the only companies that has expertise in bio-synthetic production of these compounds that we discover this stevia enzyme could produce a novel class of cannabinoid glycoside compounds.

FP: So what are some of the main advantages that Vitality has over other companies in the same space?

RB: You know, there are very few companies operating as cannabinoid pharmaceutical companies. A reason for that is that it’s generally very difficult for them to obtain significant IP protection.

That’s because THC and CBD are natural products after all. And nobody owns those compounds. There are companies like GW Pharmaceuticals who has filed and obtained patents on a relatively narrow applications or formulations of cannabinoids. But nobody owns THC or CBD. And so as a result, it’s very difficult for new entrants to enter this market without any significant IP.

You know that IP is really at the core of any successful drug development or biotech company. And so we were very fortunate in late 2015, that we discovered this novel class of cannabinoid prodrugs that are called cannabosides.

It’s not only that you have something that you own, where you can obtain composition of matter intellectual property on it. But it’s also important for that product to do something that’s really differentiated or distinguished within the market and that’s really in high demand.

It’s very well established that cannabinoids can have effects on GI conditions including severe autoimmune conditions like Crohn’s disease and ulcerative colitis. There have already been independent clinical trials that showed that just an eight week course of treatment with cannabinoids was able to induce remission in almost half of Crohn’s disease patients that were drug-resistant. So, these patients had failed all FDA-approved treatments. They were not responding to TNF-alpha inhibitors or corticosteroids. And then an eight-week course of treatment with cannabinoids put about half of them into remission.

FP: Wow.

RB: And so, many patients and patient advocates like parents of kids with pediatric Crohn’s disease; they’re really clamouring for cannabinoids.

What we’re doing is enabling them to use those through gut-restricted compounds that avoid psychoactivity. That way you can avoid any of the issues or remove the principal obstacle that you have when pediatric gastroenterologists are asked about cannabinoids.

FP: What is the size and potential of that Crohn’s disease market?

RB: The Crohn’s disease market is (you know) a large one. And it’s dominated by TNF-alpha inhibitors and it’s about a 10 billion dollar annual market for FDA-approved treatments.

FP: Wow. OK. So any kind of major breakthrough in there is gonna get quite the response from the market. What are some of the next big things that are on deck for Vitality going forward?

RB: So the company over the past year has really been focused on our pre-clinical package that we’re preparing for the FDA and for other regulators around the world to support entry into clinical trials and support the proof-of-concept trials where we intend to demonstrate efficacy based compounds in conditions like inflammatory bowel disease, irritable bowel syndrome, and narcotic bowel syndrome, which is a severe form of opiate-induced abdominal pain. So, next year in 2018, a major focus will be initiation of Phase II trials and obtaining clinical proof-of-concept data with our compounds.

FP: So, to our listeners: If you want to find Vitality Biopharma, you can find them at Vitality dot bio (www.vitality.bio) and their ticker symbol is VBIO and that’s on the OTC, is that correct, Robert?

RB: That’s correct.

FP: Awesome. Thanks again Robert. And we’ll talk to you soon.

RB: My pleasure, thanks a lot.

 

DISCLAIMER:
This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on VBIO (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety. FinancialPress.com profiles are not a solicitation or recommendation to buy, sell or hold securities. FinancialPress.com is a paid advertiser and is not offering securities for sale. Neither FinancialPress.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by FinancialPress.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. FinancialPress.com does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers. Information presented by FinancialPress.com may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur. 

THIS SITE IS PROVIDED BY FINANCIALPRESS.COM ON AN “AS IS” AND “AS AVAILABLE” BASIS. FINANCIALPRESS.COM MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK. TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, FINANCIALPRESS.COM DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. FINANCIALPRESS.COM DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM FINANCIALPRESS.COM ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. FINANCIALPRESS.COM, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES. CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS. 


By using FinancialPress.com, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable. The website contains links to other related World Wide Web Internet sites and resources. FinancialPress.com is not responsible for the availability of these outside resources, or their contents, nor does FinancialPress.com endorse nor is FinancialPress.com responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall FinancialPress.com be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster. You agree to indemnify and hold FinancialPress.com, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification. 

FinancialPress.com is owned and operated by Stock Social Inc. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). We publish the Information on our website, financialpress.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers Vitality Biopharma, Inc. FinancialPress.com has been hired by Vitality Biopharma, Inc. (VBIO) and also an unrelated third party, Full Service Media / Pyronix Media Inc., for a period beginning on October 11, 2017 and is scheduled to end on December 7, 2017 to publicly disseminate information about Vitality Biopharma, Inc. (VBIO) via website, native ads, social media and email. We have been issued 32,468 restricted shares for a hold period of six months from Vitality Biopharma Inc., and a total of one hundred and fifty thousand US dollars from Full Service Media / Pyronix Media Inc. We will update any changes to our compensation.  


Vitality Biopharma Inc. (VBIO) is a penny stock, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, TSX, CSE, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar or Sedar database or other available public sources. We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. 

We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: 

• An independent adviser or consultant; 

• A fortune teller; 

• An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; 

• A broker-dealer or an individual acting in the capacity of a registered representative or broker; 

• A stock picker; 

• A securities trading expert; 

• A securities researcher or analyst; 

• A financial planner or one who engages in financial planning; 

• A provider of stock recommendations; 

• A provider of advice about buy, sell or hold recommendations as to specific securities; or 

• An agent offering or securities for sale or soliciting their purchase. 


There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses. Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information. We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, TSX, CASE, NASDAQ, NYSE, Edgar, Sedar or other available public sources. We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. Any investment in the Profiled Issuers involves a high degree of risk and uncertainty.

The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below. We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate. If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment. The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities. The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance. You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor. When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses. The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers. We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you. If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com. FinancialPress.com, reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time


To contact The Financial Press, please contact us at: newsroom@financialpress.com

 

Share.

Comments are closed.